Dexamethasone-netilmicin: A new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery

Eye

Volumn 21, Issue 1, 2007, Pages 58-64

  Russo, S ^a   Papa, V ^a   Di Bella, A ^a   Favero, A ^a   Radulescu, C ^a   Gafencu, O ^b   Carstocea, B ^b   Milazzo, G ^a  

^a SIFI SpA   (Italy)

^b Central Military Hospital Bucharest   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DEXAMETHASONE PLUS TOBRAMYCIN; NETILMICIN;

ADULT; AGED; ANTERIOR EYE CHAMBER DISEASE; ARTICLE; BLURRED VISION; CATARACT; CATARACT EXTRACTION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EDEMA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE BURNING; EYE INFECTION; EYE INFLAMMATION; EYELID EDEMA; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LACRIMAL GLAND DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PHOTOPHOBIA; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SLIT LAMP; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 33846046078     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702123     Document Type: Article

References (38)

1. Rowen S. Preoperative and postoperative medications used for cataract surgery. Curr Opin Ophthalmol 1999; 10: 29-35.
2. Simone JN, Whitacre MM. Effects of anti-inflammatory drugs following cataract extraction. Curr Opin Ophthalmol 2001; 12: 63-67.
3. Abel Jr R, Abel AD. Perioperative antibiotic, steroid, and nonsteroidal anti-inflammatory agents in cataract intraocular lens surgery. Curr Opin Ophthalmol 1997; 8: 29-32.
4. Liesegang TJ. Use of antimicrobials to prevent postoperative infection in patients with cataracts. Curr Opin Ophthalmol 2001; 12: 68-74.
5. Soriano ES, Nishi M. Endophthalmitis: Incidence and prevention. Curr Opin Ophthalmol 2005; 16: 65-70.
6. Stewart RH, Kimbrough RL, Smith JP, deFaller JM. Use of steroid/ antibiotic prophylaxis in intraocular lens implantation: A double-masked study v placebo. Ann Ophthalmol 1983; 15: 24-28.
7. Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA. Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology 1997; 104: 334-342.
8. Hugues FC, Le Jeunne C. Systemic and local tolerability of ophthalmic drug formulations. An update. Drug Saf 1993; 8: 365-380.
9. Notivol R, Bertin D, Amin D, Whitling A, Kennedy M, Cockrum PC. Comparison of topical tobramycin-dexamethasone with dexamethasone-neomycin-polymyxin and neomycin-polymyxin-gramicidin for control of inflammation after cataract surgery: Results of a multicenter, prospective, three-arm, randomized, double-masked, controlled, parallel-group study. Clin Ther 2004; 26: 1274-1285.
10. Nielsen RH. The use of dexamethasone in ophthalmologic steroid therapy: a preliminary report. Arch Ophthalmol 1959; 62: 438-444.
11. Gordon DM. Use of dexamethasone in eye disease. JAMA 1960; 172: 311-312.
12. Drews RC. Management of postoperative inflammation: Dexamethasone vs flurbiprofen, a quantitative study using the new Flare Cell Meter. Ophthalmic Surg 1990; 21: 560-562.
13. Othenin-Girard P, Tritten JJ, Pittet N, Herbort CP. Dexamethasone vs diclofenac sodium eyedrops to treat inflammation after cataract surgery. J Cataract Refract Surg 1994; 20: 9-12.
14. Leibowitz HM, Kupferman A, Stewart RH, Kimbrough RL. Evaluation of dexamethasone acetate as a topical ophthalmic formulation. Am J Ophthalmol 1978; 86: 418-423.
15. Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology 2002; 109: 1887-1891.
16. Campoli-Richards DM, Chaplin S, Sayce RH, Goa KL. Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1989; 38: 703-756.
17. Papa V, Aragona P, Scuderi AC, Blanco AR, Zola P, Di Bella A et al. Treatment of acute bacterial conjunctivitis with topical netilmicin. Cornea 2002; 21: 43-47.
18. Bonfiglio G, Scuderi AC, Russo G. Netilmicin: In vitro activity, time-kill evaluation and postantibiotic effect on microorganisms isolated from ocular infections. Chemotherapy 2001; 47: 117-122.
19. Kraff MC, Martin RG, Neumann AC, Weinstein AJ. Efficacy of diclofenac sodium ophthalmic solution vs placebo in reducing inflammation following cataract extraction and posterior chamber lens implantation. J Cataract Refract Surg 1994; 20: 138-144.
20. Laurell CG, Zetterstrom C. Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. Br J Ophthalmol 2002; 86: 1380-1384.
21. Papa V, Milazzo G, Santocono M, Servolle V, Sourdille P, Santiago PY et al. Naproxen ophthalmic solution to manage inflammation after phacoemulsification. J Cataract Refract Surg 2002; 28: 321-327.
22. Missotten L, Richard C, Trinquand C. Topical 0.1% indomethacin solution vs topical 0.1% dexamethasone solution in the prevention of inflammation after cataract surgery. The Study Group. Ophthalmologica 2001; 215: 43-50.
23. Stewart RH, Smith JP, Rosenthal AL. Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphate. Curr Eye Res 1984; 3: 835-839.
24. El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol 2001; 12: 4-8.
25. Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol 1992; 36: 259-284.
26. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002; 42: 1-11.
27. Sanders DR, Kraff M. Steroidal and nonsteroidal antiinflammatory agents. Effect on postsurgical inflammation and blood-aqueous humor barrier breakdown. Arch Ophthalmol 1984; 102: 1453-1456.
28. Sherif Z, Pleyer U. Corticosteroids in ophthalmology: past-present-future. Ophthalmologica 2002; 216: 305-315.
29. Bezan DJ. Postoperative care of the cataract patient. In: Bartlett JD JS (ed). Clinical Ocular Pharmacology. Butterworth-Heinemann: Boston, MA, 1995, pp 793-808.
30. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999; 20: 250-278; quiz 279-280.
31. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000; 11: 478-483.
32. Roberts CW, Brennan KM. A comparison of topical diclofenac with prednisolone for postcataract inflammation. Arch Ophthalmol 1995; 113: 725-727.
33. Sacca S, Marletta A, Pascotto A, Barabino S, Rolando M, Giannetti R et al. Daily tonometric curves after cataract surgery. Br J Ophthalmol 2001; 85: 24-29.
34. Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. J. The demonstration of three levels of response. Invest Ophthalmol 1965; 26: 187-197.
35. Milazzo G, Papa V, Carstocea B, Chercota G, Rodica. P, Gafencu O et al. Topical netilmicin compared with tobramycin in the treatment of external ocular infection. Int J Clin Pharmacol Ther 1999; 37: 243-248.
36. Papa V, Leonardi A, Getuh C, Pacelli V, Russo P, Milazzo G. Effect of ofloxacin and netilmicin on human corneal and conjunctival cells in vitro. J Ocular Pharm Ther 2003; 19: 535-545.
37. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001; 18: 205-215.
38. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004; 23: 490-496.